FY2024 Earnings Estimate for PolyPid Issued By HC Wainwright

PolyPid Ltd. (NASDAQ:PYPD) – Equities researchers at HC Wainwright decreased their FY2024 earnings estimates for PolyPid in a report released on Monday, December 16th. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($4.83) per share for the year, down from their prior forecast of ($4.39). HC Wainwright currently has a “Buy” rating and a $14.00 target price on the stock. The consensus estimate for PolyPid’s current full-year earnings is ($4.39) per share. HC Wainwright also issued estimates for PolyPid’s Q4 2024 earnings at ($1.05) EPS, Q1 2025 earnings at ($0.86) EPS, Q2 2025 earnings at ($0.71) EPS, Q3 2025 earnings at ($0.57) EPS, Q4 2025 earnings at ($0.40) EPS and FY2025 earnings at ($2.41) EPS.

Separately, Craig Hallum started coverage on PolyPid in a report on Monday, November 4th. They set a “buy” rating and a $10.00 target price on the stock.

PolyPid Stock Down 8.0 %

Shares of NASDAQ PYPD opened at $3.22 on Thursday. The stock has a market cap of $15.45 million, a PE ratio of -0.41 and a beta of 1.33. The company has a current ratio of 1.00, a quick ratio of 1.00 and a debt-to-equity ratio of 1.17. PolyPid has a 12-month low of $2.37 and a 12-month high of $9.20. The company has a 50-day moving average of $3.28 and a 200 day moving average of $3.56.

Institutional Investors Weigh In On PolyPid

An institutional investor recently bought a new position in PolyPid stock. Stonepine Capital Management LLC bought a new stake in PolyPid Ltd. (NASDAQ:PYPD) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 138,504 shares of the company’s stock, valued at approximately $476,000. Stonepine Capital Management LLC owned about 2.89% of PolyPid at the end of the most recent reporting period. 26.47% of the stock is currently owned by institutional investors and hedge funds.

PolyPid Company Profile

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.